A new PwC survey reveals a strong need to fully embrace alternative commercial methods-not in a blind frenzy but through careful evaluation of which new sales strategies have true innovative potential.
Rolf Fricker
Advertisement
Articles by Rolf Fricker
Advertisement
Latest Updated Articles
Tomorrow’s Selling Strategies: Invest & TestMarch 8th 2015
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909
2
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
3
Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data
4
New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report
5